STEINMAN LAWRENCE - 04 Sep 2023 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Role
Director
Signature
/s/ Lawrence Steinman, M.D.
Issuer symbol
ATNF
Transactions as of
04 Sep 2023
Transactions value $
$0
Form type
4
Filing time
06 Sep 2023, 19:55:41 UTC
Previous filing
15 Jun 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATNF Common Stock 48.1K 04 Sep 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNF Non-Qualified Stock Option (right to buy) Award $0 +15K $0.00 15K 04 Sep 2023 Common Stock 15K $0.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Granted in consideration for services rendered and to be rendered as a member of the Board of Directors for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F2 The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.